ATE370235T1 - Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden - Google Patents

Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden

Info

Publication number
ATE370235T1
ATE370235T1 AT95933105T AT95933105T ATE370235T1 AT E370235 T1 ATE370235 T1 AT E370235T1 AT 95933105 T AT95933105 T AT 95933105T AT 95933105 T AT95933105 T AT 95933105T AT E370235 T1 ATE370235 T1 AT E370235T1
Authority
AT
Austria
Prior art keywords
antibodies
peptides
humanization
present
humanized
Prior art date
Application number
AT95933105T
Other languages
English (en)
Inventor
Couto Fernando Do
Roberto Ceriani
Jerry Peterson
Original Assignee
Cancer Res Fund Of Contra Cost
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Fund Of Contra Cost filed Critical Cancer Res Fund Of Contra Cost
Application granted granted Critical
Publication of ATE370235T1 publication Critical patent/ATE370235T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT95933105T 1994-09-16 1995-09-14 Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden ATE370235T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30786894A 1994-09-16 1994-09-16
US48759895A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ATE370235T1 true ATE370235T1 (de) 2007-09-15

Family

ID=26975968

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95933105T ATE370235T1 (de) 1994-09-16 1995-09-14 Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden

Country Status (10)

Country Link
US (1) US20090010848A1 (de)
EP (1) EP0784684B8 (de)
AT (1) ATE370235T1 (de)
AU (1) AU707159B2 (de)
CA (1) CA2200097A1 (de)
DE (1) DE69535562T2 (de)
DK (1) DK0784684T3 (de)
ES (1) ES2293642T3 (de)
PT (1) PT784684E (de)
WO (1) WO1996008565A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CU23097A1 (es) * 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
PT2311873T (pt) * 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc Anticorpo monoclonal específico para m-csf e respetivos usos
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2013139956A1 (en) * 2012-03-22 2013-09-26 Thrombogenics Nv Antibodies abrogating cell binding to lactadherin
US20180036442A1 (en) 2014-07-29 2018-02-08 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
AU2015295687C1 (en) * 2014-07-29 2019-10-17 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
JP6917357B2 (ja) 2015-07-17 2021-08-11 フレイエ ユニヴェルシテイト ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｔｅｉｔ Ｂｒｕｓｓｅｌ 癌治療に使用する放射標識抗体断片

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
EP0674710B1 (de) * 1992-11-16 2003-05-02 Cancer Research Fund Of Contra Costa Peptide mit breiter neoplastischer spezifizität

Also Published As

Publication number Publication date
DK0784684T3 (da) 2007-12-17
PT784684E (pt) 2007-11-23
AU707159B2 (en) 1999-07-01
US20090010848A1 (en) 2009-01-08
EP0784684B1 (de) 2007-08-15
CA2200097A1 (en) 1996-03-21
AU3588795A (en) 1996-03-29
ES2293642T3 (es) 2008-03-16
DE69535562D1 (de) 2007-09-27
WO1996008565A3 (en) 1996-07-11
WO1996008565A2 (en) 1996-03-21
DE69535562T2 (de) 2008-06-26
EP0784684A2 (de) 1997-07-23
EP0784684B8 (de) 2008-03-26

Similar Documents

Publication Publication Date Title
ATE370235T1 (de) Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden
DE69119211T2 (de) Cdr-gepfropfte anti-cea-antikörper und ihre herstellung
DK0781845T3 (da) Anti-HMFG-antistoffer og fremgangsmåder til fremstilling heraf
EA200301098A1 (ru) Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей
EP1362868A3 (de) Humanisierte und chimäre monoklonale Antikörper die den Rezeptor für epidermalen Wachstumfaktor (EGF-R) binden
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
FI981799A (fi) DNA-molekyylejä, jotka koodaavat CD25 sitovia molekyylejä
NZ303375A (en) Monoclonal antibodies specific for different epitopes of human gp39 and diagnostic and therapeutic methods using them
AU2003220525A8 (en) Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
DE69029808D1 (de) Monoklonale antikörper
RU2380377C2 (ru) Nogo-A-СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0784684

Country of ref document: EP

REN Ceased due to non-payment of the annual fee